Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Mesenchymal Stromal Cells Primed with Paclitaxel Provide a New Approach for Cancer Therapy

Open access
Pessina, Augusto, Bonomi, Arianna, Coccè, Valentina, Invernici, Gloria, Navone, Stefania, Cavicchini, Loredana, Sisto, Francesca, Ferrari, Maura, Viganò, Lucia, Locatelli, Alberta, Ciusani, Emilio, Cappelletti, Graziella, Cartelli, Daniele, Arnaldo, Caruso, Parati, Eugenio, Marfia, Giovanni, Pallini, Roberto, Falchetti, Maria Laura, Alessandri, Giulio·2011·PLoS ONE

Abstract

BACKGROUND: Mesenchymal stromal cells may represent an ideal candidate to deliver anti-cancer drugs. In a previous study, we demonstrated that exposure of mouse bone marrow derived stromal cells to Doxorubicin led them to acquire anti-proliferative potential towards co-cultured haematopoietic stem cells (HSCs). We thus hypothesized whether freshly isolated human bone marrow Mesenchymal stem cells (hMSCs) and mature murine stromal cells (SR4987 line) primed in vitro with anti-cancer drugs and then localized near cancer cells, could inhibit proliferation. METHODS AND PRINCIPAL FINDINGS: Paclitaxel (PTX) was used to prime culture of hMSCs and SR4987. Incorporation of PTX into hMSCs was studied by using FICT-labelled-PTX and analyzed by FACS and confocal microscopy. Release of PTX in culture medium by PTX primed hMSCs (hMSCsPTX) was investigated by HPLC. Culture of Endothelial cells (ECs) and aorta ring assay were used to test the anti-angiogenic activity of hMSCsPTX and PTX primed SR4987(SR4987PTX), while anti-tumor activity was tested in vitro on the proliferation of different tumor cell lines and in vivo by co-transplanting hMSCsPTX and SR4987PTX with cancer cells in mice. Nevertheless, despite a loss of cells due to chemo-induced apoptosis, both hMSCs and SR4987 were able to rapidly incorporate PTX and could slowly release PTX in the culture medium in a time dependent manner. PTX primed cells acquired a potent anti-tumor and anti-angiogenic activity in vitro that was dose dependent, and demonstrable by using their conditioned medium or by co-culture assay. Finally, hMSCsPTX and SR4987PTX co-injected with human cancer cells (DU145 and U87MG) and mouse melanoma cells (B16) in immunodeficient and in syngenic mice significantly delayed tumor takes and reduced tumor growth. CONCLUSIONS: These data demonstrate, for the first time, that without any genetic manipulation, mesenchymal stromal cells can uptake and subsequently slowly release PTX. This may lead to potential new tools to increase efficacy of cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0028321

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 167

Metadata

Authors
Pessina, A., Bonomi, A., Coccè, V., Invernici, G., Navone, S., Cavicchini, L., Sisto, F., Ferrari, M., Viganò, L., Locatelli, A., Ciusani, E., Cappelletti, G., Cartelli, D., Arnaldo, C., Parati, E., Marfia, G., Pallini, R., Falchetti, M. L., & Alessandri, G.
Venue
PLoS ONE
Published
2011-12-20
Volume
6
Issue
12
Pages
e28321
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2028599863
Cited by
167
References
6
FWCI
3.32
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mesenchymal Stromal Cells Primed with Paclitaxel Provide a New Approach for Cancer Therapy. https://app.cochat.ai/papers/10.1371/journal.pone.0028321
The paper
Pessina, A., Bonomi, A., Coccè, V., Invernici, G., Navone, S., Cavicchini, L., Sisto, F., Ferrari, M., Viganò, L., Locatelli, A., Ciusani, E., Cappelletti, G., Cartelli, D., Arnaldo, C., Parati, E., Marfia, G., Pallini, R., Falchetti, M. L., & Alessandri, G. (2011). Mesenchymal Stromal Cells Primed with Paclitaxel Provide a New Approach for Cancer Therapy. PLoS ONE. https://doi.org/10.1371/journal.pone.0028321

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.